Single User
£3188
PDF
38 pages

Hypertrophic Cardiomyopathy Forecast in 8 Major Markets 2015-2025


Hypertrophic cardiomyopathy (HCM) is a disease that contains an autosomal dominant inheritance pattern and is a moderately common “transmitted” genetic disease. The disease, characterized by hypertrophy in the left ventricle, cannot be explained by the presence of other clinical symptoms, such as hypertension. This report provides the current prevalent population for HCM across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the types, occlusion locations and the prevalence of associated disorders of HCM. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of HCM have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for HCM include:

  • Chronic heart failure
  • Angina pectoris
  • Atrial fibrillation
  • Tachycardia

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global HCM’s market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of HCM and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on HCM’s prevalent population.
  • Examination of the prevalence of the different causative gene mutations for HCM.
  • Identify sub-populations within HCM which require treatment.
  • Gain an understanding of the specific markets that have the largest number of HCM patients.

Table of Contents

  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors and Prevention
  • Diagnosis of the Disease
  • Variation by Geography/ Ethnicity
  • Disease Prognosis and Clinical Course
  • Key Co-Morbid Conditions / Features associated with the Disease
  • Methodology for Quantification of Patient Numbers
  • Top-Line Prevalence for Nocturia
  • Main Features of Nocturia Patients
    • Aetiology
    • C-reactive Protein Status
    • Frequency of Night-Time Voids
    • Concomitant Conditions for Nocturia
    • BMI Status of Patients with Nocturia
  • Abbreviations used in the Report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix

List of Tables and Figures

  • Algorithm for the Definition and Treatment of Nocturia
  • Prevalence of Nocturia, total (000s)
  • Prevalence of Nocturia, males (000s)
  • Prevalence of Nocturia, females (000s)
  • Nocturia Patients by Aetiology, total (000s)
  • Nocturia Patients by CRP level, total (000s)
  • Frequency of Night-Time Voids in Patients with Nocturia, total (000s)
  • Prevalence of Diabetes in Patients with Nocturia, total (000s)
  • Prevalence of Hypertension in Patients with Nocturia, total (000s)
  • Prevalence of BPH in Patients with Nocturia, total (000s)
  • Prevalence of CHF in Patients with Nocturia, total (000s)
  • Prevalence of Urinary Incontinence in Patients with Nocturia, total (000s)
  • Prevalence of Multiple Sclerosis in Patients with Nocturia, total (000s)
  • BMI Status of Patients with Nocturia, total (000s)
  • Abbreviations and Acronyms used in the Report
  • USA Prevalence of Nocturia by 5-yr age cohort, males (000s)
  • USA Prevalence of Nocturia by 5-yr age cohort, females (000s)
  • France Prevalence of Nocturia by 5-yr age cohort, males (000s)
  • France Prevalence of Nocturia by 5-yr age cohort, females (000s)
  • Germany Prevalence of Nocturia by 5-yr age cohort, males (000s)
  • Germany Prevalence of Nocturia by 5-yr age cohort, females (000s)
  • Italy Prevalence of Nocturia by 5-yr age cohort, males (000s)
  • Italy Prevalence of Nocturia by 5-yr age cohort, females (000s)
  • Spain Prevalence of Nocturia by 5-yr age cohort, males (000s)
  • Spain Prevalence of Nocturia by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of Nocturia by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of Nocturia by 5-yr age cohort, females (000s)
  • Brazil Prevalence of Nocturia by 5-yr age cohort, males (000s)
  • Brazil Prevalence of Nocturia by 5-yr age cohort, females (000s)
  • Japan Prevalence of Nocturia by 5-yr age cohort, males (000s)
  • Japan Prevalence of Nocturia by 5-yr age cohort, females (000s)
Brazil, France, Germany, Italy, Japan, Spain, United Kingdom, United States of America